Concepedia

Ultra-low-dose intravitreal bevacizumab for the treatment of retinopathy of prematurity: a case series

Roxane J. Hillier, Alan Connor, Ayad Shafiq

British Journal of Ophthalmology · 2017 · 24 citations · 15 references

DOI

Abstract

0.16 mg IVB is effective in the treatment of severe and posterior ROP, with no adverse ocular outcomes occurring in our series.

References

15

Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity

Helen A. Mintz-Hittner, Kathleen A. Kennedy, Alice Z. Chuang · New England Journal of Medicine · 2011 · 1.4K citations · Full text

Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial.

William V. Good · PubMed · 2004 · 540 citations

Serum Concentrations of Bevacizumab (Avastin) and Vascular Endothelial Growth Factor in Infants With Retinopathy of Prematurity

Tatsuhiko Sato, Kazuko Wada, Hitomi Arahori et al. · American Journal of Ophthalmology · 2011 · 321 citations

, , +7

Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity

Julie Morin, Thuy Mai Luu, Rosanne Superstein et al. · PEDIATRICS · 2016 · 285 citations

Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy

Helen A. Mintz-Hittner, Megan M. Geloneck, Alice Z. Chuang · Ophthalmology · 2016 · 201 citations · Full text

, , +8